PRELIMINARY SCIENTIFIC PROGRAMME
|
|||||||||
| PLENARY LECTURES | |||||||||
| Saturday, June 26th, 2010 | |||||||||
| Eating oneself for immunity and tolerance: the role of autophagy in the immune system | |||||||||
| Ludger Klein, Munich, Germany | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| Ciliopathy: from bench to bedside | |||||||||
| Gerd Walz, Freiburg, Germany | |||||||||
| Monday, June 28th, 2010 | |||||||||
| Approaches to and biomarkers of transplantation tolerance | |||||||||
| Robert Lechler, London, UK | |||||||||
| return to top | |||||||||
| MINI LECTURES | |||||||||
| Basic science | |||||||||
| Suppressors of cytokine signaling (SOCS) and kidney diseases: a potential novel therapeutic target | |||||||||
| Jesus Egido, Madrid, Spain | |||||||||
| Innate immune responses in ischemia/reperfusion injury | |||||||||
| Sandrine Florquin, Amsterdam, Netherlands | |||||||||
| Dialysis | |||||||||
How to assess extracellular volume and “dry weight” in dialysis patients – is bioimpedance the answer? |
|||||||||
| Adrian Covic, Iasi, Romania | |||||||||
| Treatment of hypertension in dialysis patients | |||||||||
| Olof Heimbürger, Stockholm, Sweden | |||||||||
| Chronic dialysis since the first month of life: long-term results | |||||||||
| Pierre Cochat, Lyon, France | |||||||||
| Sex differences for chronic kidney disease: a platform for treatment strategies? | |||||||||
| Jesus Carrero, Stockholm, Sweden | |||||||||
| Chronic kidney disease | |||||||||
| The year after – How do KDIGO CKD-MBD guidelines impact on clinical practice? | |||||||||
| Markus Ketteler, Coburg, Germany | |||||||||
| Body mass index and mortality in dialysis population | |||||||||
| Renée de Mutsert, Leiden, Netherlands | |||||||||
| Sleep disorders in renal patients | |||||||||
| Francesca Mallamaci, Reggio Calabria | |||||||||
| Transplantation | |||||||||
| Interplay between ischemia/reperfusion injury and alloreactivity | |||||||||
| Juan Torras, Barcelona, Spain | |||||||||
| Optimal preservation for extended criteria kidneys | |||||||||
| Rutdger Ploeg, Groningen, The Netherlands | |||||||||
| Subclinical rejection: to treat or not? | |||||||||
| Johan de Fijter, Leiden, Netherlands | |||||||||
| Transplantation in children with primary hyperoxaluria | |||||||||
| Dirk E. Mueller-Wiefel, Hamburg, Germany | |||||||||
| Acute kidney injury | |||||||||
| Standard versus intensified dialysis in AKI in intensive care units | |||||||||
| Danilo Fliser, Homburg/Saar, Germany | |||||||||
| Clinical nephrology | |||||||||
| Novel treatments for ANCA-associated vasculitis | |||||||||
| Caroline Savage, Birmingham, UK | |||||||||
| Proteinuria triggers immune responses | |||||||||
| Ariela Benigni, Bergamo, Italy | |||||||||
| Notch receptors in glomerulonephritis | |||||||||
| Peter Mertens, Magdeburg, Germany | |||||||||
| The role of immunoproteasome in the pathogenesis of IgA nephropathy | |||||||||
| Alessandro Amore, Turin, Italy | |||||||||
| Diabetes | |||||||||
| Lipid profile and renal function in type 1 diabetes | |||||||||
| Nina Tolonen, Helsinki, Finland | |||||||||
| Inflammation and proteinuria in diabetic patients | |||||||||
| Mahmut Ilker Yilmaz, Ankara, Turkey | |||||||||
| Bone disease | |||||||||
| CKD-related mineral and bone disorders | |||||||||
| Angel Argilés, Montpellier, France | |||||||||
| The dynamic of PTH secretion in response to calcium; the effect of calcimimetics | |||||||||
| Mariano Rodríguez, Córdoba, Spain | |||||||||
| Hypertension | |||||||||
| The metabolic syndrome in hypertension | |||||||||
| Josep Redon, Valencia, Spain | |||||||||
| Blood pressure measurement in CKD | |||||||||
| Rajiv Agarwal, Indianapolis, USA | |||||||||
| return to top | |||||||||
| SYMPOSIA | |||||||||
| Saturday, June 26th, 2010 | |||||||||
| • Podocytes | |||||||||
| - Podocytes - an outside view of the glomerulus | |||||||||
| Agnes Fogo, Nashville, USA | |||||||||
| - Podocytes regeneration | |||||||||
| Paola Romagnani, Florence, Italy | |||||||||
| - The role of parietal cells in health and disease | |||||||||
| Marcus J. Moeller, Aachen, Germany | |||||||||
| - Transcription factors as therapeutic targets in podocytes | |||||||||
| Peter Mathieson, Bristol, UK | |||||||||
| • Pathophysiology of AKI | |||||||||
| - Hypoxia and renal injury | |||||||||
| Michael S. Wiesener, Erlangen, Germany | |||||||||
| - TWEAK/FN14 in acute kidney injury | |||||||||
| Alberto Ortiz, Madrid, Spain | |||||||||
| - Inflammatory mechanisms in AKI | |||||||||
| Marc De Broe, Antwerp, Belgium | |||||||||
| - Monocytes derived cells in acute kidney injury | |||||||||
| Jeremy Hughes, Edinburg, UK | |||||||||
| • Registry | |||||||||
| - EVEREST - factors affecting RRT incidence and treatment modality choice | |||||||||
| Fergus Caskey, Bristol, United Kingdom | |||||||||
| - EVEREST - factors affecting patient survival | |||||||||
| Anneke Kramer, Amsterdam, The Netherlands | |||||||||
| - Haemodialysis-Peritoneal dialysis comparisons | |||||||||
| Moniek van de Luijtgaarden, Amsterdam, The Netherlands | |||||||||
| - Trends in access to transplantation | |||||||||
| Vianda Stel, Amsterdam, The Netherlands | |||||||||
| - The complementary use of Registry data for research into rare diseases | |||||||||
| Cristoph Wanner, Würzburg, Germany | |||||||||
| • Nephrolithiasis and nephrocalcinosis | |||||||||
| - Nephrocalcinosis: new insights into mechanisms and consequences | |||||||||
| Benjamin A. Vervaet, Antwerp, Belgium | |||||||||
| - Calcium receptors in mineral ion transport | |||||||||
| Giuseppe Vezzoli, Rome, Italy | |||||||||
| - Management of hypercalciuria | |||||||||
| Andrew Schwaderer, Ohio, USA | |||||||||
| - Non-drug induced nephrotoxicity | |||||||||
| Justine Bacchetta, Bron, France | |||||||||
| • Focal segmental glomerulosclerosis | |||||||||
| - Advanced glycation end-products in diabetic nephropathy: suppression of neutropilin expression to promote focal glomerulosclerosis | |||||||||
| Gunter Wolf, Jena, Germany | |||||||||
| - Cardiotrophin-like cytokine-1, potential FSGS permeability factor | |||||||||
| Virginia J. Savin, Milwaukee, USA | |||||||||
| - Discovery of MYH9 genetic variations and advanced focal segmental glomerular sclerosis | |||||||||
| Rulan S. Parekh, Toronto, Canada | |||||||||
| - Update on the treatment of idiopathic FSGS | |||||||||
| Alain Meyrier, Paris, France | |||||||||
| • Peritoneal Dialysis 1 | |||||||||
| - Dynamic interactions between peritoneum and abdominal adipocytes: the effect of peritoneal dialysis solutions | |||||||||
| Daniel Teta, Lausanne, Switzerland | |||||||||
| - Peritoneal functional pathology: the role of immunohistochemistry in the understanding of peritoneal pathophysiology | |||||||||
| José Jiménez-Heffernan, Madrid, Spain | |||||||||
| - Pathophysiology of the peritoneal interstitium and mesothelial cells in ultrafiltration failure (UFF) | |||||||||
| Bengt Rippe, Lund, Sweden | |||||||||
| - Biomarkers in peritoneal dialysis | |||||||||
| Raymond T. Krediet, Amsterdam, Netherlands | |||||||||
| • Cardiovascular risk biomarkers | |||||||||
| - Biomarkers: when is it justified to incorporate a new biomarker into clinical practice? | |||||||||
| Carmine Zoccali, Reggio Calabria, Italy | |||||||||
| - Inflammation in chronic kidney disease. Etiology, prognosis and treatment | |||||||||
| Peter Stenvinkel, Stockholm, Sweden | |||||||||
| - Cardiac natriuretic peptides and risk stratification in CKD | |||||||||
| Christiane Drechsler, Würzburg, Germany | |||||||||
| - Cardiovascular risk biomarkers in renal transplantation | |||||||||
| Didier Ducloux, Besançon, France | |||||||||
| • KDIGO Symposium: guidelines in AKI | |||||||||
| • Protein bound uremic toxins | |||||||||
| - Metabolism | |||||||||
| Raymond Vanholder, Gent, Belgium | |||||||||
| - Biological effects | |||||||||
| Joachim Jankowski, Berlin, Germany | |||||||||
| - Removal of protein bound toxins by hemodialysis | |||||||||
| Horst-Dieter Lemke, Obernburg, Germany | |||||||||
| - New insights from clinical studies | |||||||||
| Ziad Massy, Amiens, France | |||||||||
| • Renal transplantation: Clinical Pharmacology | |||||||||
| - Impact of pharmacogenetic testing on dosing of immunosuppressive drugs | |||||||||
| Teunis van Gelder, Rotterdam, Netherlands | |||||||||
| - Optimization of immunosuppressants dosing in renal transplantation | |||||||||
| Yannick Le Meur, Limoges, France | |||||||||
| - Genome wide analysis and transplantation: what is it and what could it bring us? | |||||||||
| Dirk R. Kuypers, Louvain, Belgium | |||||||||
| - Population pharmacokinetics in renal transplantation | |||||||||
| Manuel Oriol, Lausanne, Switzerland | |||||||||
| • The bone (adipocyte) vascular axis | |||||||||
| - Klotho, FGF23 and vitamin D: a bone-kidney story and much more | |||||||||
| Gérard Friedlander, Paris, France | |||||||||
| - Beyond Ca/P/PTH: clinical evidence of a link between the adipose tissue and bone disease in ESRD | |||||||||
| Andrzej Wiecek, Katowice, Poland | |||||||||
| - Vascular calcifications as a risk factor for cardiovascular mortality | |||||||||
| Leon Schurgers, Maastricht, Netherlands | |||||||||
| - Vascular calcification: can we control progression and regression? | |||||||||
| Jorge B. Cannata-Andía, Oviedo, Spain | |||||||||
| • Cell-driven renal repair | |||||||||
| - Stem cells and renal regeneration | |||||||||
| Uta Kunter, Aachen, Germany | |||||||||
| - Mesenchymal stem cells in organ transplantation | |||||||||
| Federica Casiraghi, Bergamo, Italy | |||||||||
| - Potential repairing process of renal progenitor cells in tubular damage | |||||||||
| Francesco Paolo Schena, Bari, Italy | |||||||||
| - Stem cells and whole organ scaffolds: implications for kidney regenerative medicine | |||||||||
| Edward A. Ross, Gainesville, USA | |||||||||
| • IgA nephropathy | |||||||||
| - Oxidative stress modulates the nephrotoxicity of aberrantly glycosylated IgA1 | |||||||||
| Rosanna Coppo, Turin, Italy | |||||||||
| - C4d deposition in IgA nephropathy | |||||||||
| Mario Espinosa, Córdoba, Spain | |||||||||
| - Renal biopsy in IgA nephropathy: the Oxford classification and beyond | |||||||||
| Ian Roberts, Oxford, UK | |||||||||
| - IgA nephropathy: a review of recent and ongoing treatment studies | |||||||||
| Claudio Pozzi, Cinisello Balsamo, Italy | |||||||||
| • Haemodialysis | |||||||||
| - Biocompatibility and genomics in dialysis | |||||||||
| Rainer Oberbauer, Linz, Austria | |||||||||
| - Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function | |||||||||
| Tienush Rassaf, Düsseldorf, Germany | |||||||||
| - Impact of a haemodialysis session for myocardial perfusion | |||||||||
| Christoph W. McIntyre, Derby, Uk | |||||||||
| - Arrhythmias in dialysis patients | |||||||||
| Walter H. Hörl, Vienna, Austria | |||||||||
| • Role of physical fitness in CKD patients | |||||||||
| - Physical fitness - an integral part of comprehensive care of CKD patients | |||||||||
| Rolfdieter Krause, Berlin, Germany | |||||||||
| - The effects of exercise training on muscle with special reference to patients with CKD | |||||||||
| Tom Mercer, Edinburgh, United Kingdom | |||||||||
| - The impact of physical fitness on morbidity and quality of life in patients with CKD | |||||||||
| Kirsten Anding-Rost, Bischofswerda, Germany | |||||||||
| • European Cardiovascular and Renal Medicine (EURECAM) | |||||||||
| - EURECAM mission and results of surveys | |||||||||
| Carmine Zoccali, Reggio Calabria, Italy | |||||||||
| - The potential of Registries for scientific research in Cardiovascular and Renal Medicine | |||||||||
| Friedo W. Dekker, Leiden, The Netherlands | |||||||||
| - Information provided by 24 h ambulatory blood pressure monitoring | |||||||||
| Gianfranco Parati, Milan, Italy | |||||||||
| - Potential and caveats on the use of Clinical Trials data-bases for secondary analyses in Cardiovascular and Renal Medicine | |||||||||
| Johannes Mann, Munich, Germany | |||||||||
| • Hypertension | |||||||||
| - Aldosterone-receptor antagonism in hypertension: where do we stand | |||||||||
| Anton H. van den Meiracker, Rotterdam, The Netherlands | |||||||||
| - Is aldosterone toxic for renal cells? | |||||||||
| Eric Féraille, Geneva, Switzerland | |||||||||
| - Arterial stiffness in renal transplant recipients | |||||||||
| Francis Verbeke, Ghent, Belgium | |||||||||
| - Can we treat arterial stiffness? | |||||||||
| Stéphane Laurent, Paris, France | |||||||||
| • ERA-EDTA Nephroquest Working Group | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| • Renal transplantation: the humoral barrier | |||||||||
| - ABO incompatible renal transplantation | |||||||||
| Marcel Geyer, Freiburg, Germany | |||||||||
| - Prevention and treatment of antibody-mediated rejection | |||||||||
| Denis Glotz, Paris, France | |||||||||
| - The role of costimulatory signals in antibody-mediated rejection | |||||||||
| Suzanne T. Ildstad, Louisville | |||||||||
| - Novel therapies to inhibit humoral responses: the role of proteosome inhibition | |||||||||
| Flavio Vincenti, San Francisco, USA | |||||||||
| • Is cardiorenal syndrome a new entity? | |||||||||
| - Pro | |||||||||
| Claudio Ronco, Vicenza, Italy | |||||||||
| - Con | |||||||||
| Walter H. Hörl, Vienna, Austria | |||||||||
| - Impact of various manifestations of renal dysfunction on heart failure | |||||||||
| Gerjan Navis, Groningen, The Netherlands | |||||||||
| - Continuous extracorporeal treatments in heart failure | |||||||||
| Giancarlo Marenzi, Milan, Italy | |||||||||
| • Renal physiology | |||||||||
| - Renal and extrarenal effects of Klotho | |||||||||
| Florian Lang, Tübingen, Germany | |||||||||
| - Novel genetic disorders of nephron function | |||||||||
| Robert Kleta, London, UK | |||||||||
| - Novel aspects of the renin-angiotensin-system | |||||||||
| Armin Kurtz, Regensburg, Germany | |||||||||
| - Novel aspects of sodium resorption and storage | |||||||||
| Jens Titze, Erlangen, Germany | |||||||||
| • Outcomes in renal transplantation | |||||||||
| - Current impact of HLA compatibility and immunosuppression on graft survival | |||||||||
| Gerhard Opelz, Heidelberg, Germany | |||||||||
| - Long-term outcomes of the European Senior Program | |||||||||
| Urlich Frei, Berlin, Germany | |||||||||
| - Sustained improvement of graft survival: is it feasible? | |||||||||
| Josep M. Campistol, Barcelona, Spain | |||||||||
| • Sympathetic overactivity in hypertension and in CKD | |||||||||
| - The pathogenesis and clinical relevance of sympathetic hyperactivity in chronic kidney disease | |||||||||
| Peter J. Blankestijn, Utrecht, Netherlands | |||||||||
| - Pharmacologic interference with the sympathetic system in cardiovascular and renal diseases | |||||||||
| Guido Grassi, Monza, Italy | |||||||||
| - Renal sympathetic denervation in resistant hypertension in humans | |||||||||
| Henry Krum, Melbourne, Australia | |||||||||
| • New insights into rare CKD-associated diseases | |||||||||
| - Calciphylaxis | |||||||||
| Vincent Brandenburg, Aachen, Germany | |||||||||
| - Encapsulating peritoneal sclerosis | |||||||||
| Angela M. Summers, Manchester, UK | |||||||||
| - Nephrogenic systemic fibrosis | |||||||||
| Andreas Kribben, Essen, Germany | |||||||||
| • Immune mechanisms in autoimmune nephritis | |||||||||
| - Pseudoviral immunity. The novel concept of immunity | |||||||||
| Hans Joachim Anders, Munich, Germany | |||||||||
| - The TH1 and TH17 immune response in Glomerulonephritis | |||||||||
| Oliver Steinmetz, Hamburg, Germany | |||||||||
| - Novel roles of chemokines | |||||||||
| Carla Zoja, Bergamo, Italy | |||||||||
| • When to start dialysis | |||||||||
| - Ideal time for starting renal replacement therapy | |||||||||
| Friedo W. Dekker, Leiden, Netherlands | |||||||||
| - Unplanned start on assisted peritoneal dialysis | |||||||||
| Johan Vestergaard Povlsen, Aarhus, Denmark | |||||||||
| - Which role for incremental peritoneal dialysis | |||||||||
| Giusto Viglino, Alba, Italy | |||||||||
| • Progression of renal damage | |||||||||
| - Controlling transglutaminase type 2 prevents the progression of chronic kidney disease | |||||||||
| Timothy S. Johnson, Sheffield, UK | |||||||||
| - Capillary rarefication, angiogenesis and VEGF in the progression of renal disease | |||||||||
| Gert Mayer, Innsbruck, Austria | |||||||||
| - Danger-associated molecular pattern (DAMP) molecules in progressive renal disease | |||||||||
| Detlef O. Schlöndorff, New York, USA | |||||||||
| - Growth factors in renal regeneration | |||||||||
| Josep M. Cruzado, Barcelona, Spain | |||||||||
| • KDIGO on management of glomerular diseases | |||||||||
| - Introduction | |||||||||
| John Feehally, Leicester, UK | |||||||||
| - Treatment of Minimal change nephropathy and FSGS | |||||||||
| Jack S.M. Wetzels, Nijmegen, The Netherlands | |||||||||
| - IgA nephropathy | |||||||||
| Jürgen Floege, Aachen, Germany | |||||||||
| - Membranous and membranoproliferative glomerulonephritis | |||||||||
| Richard Glassock, Los Angeles, USA | |||||||||
| - Lupus and vasculitis | |||||||||
| Fernando Fervenza, Rochester, USA | |||||||||
| • Peritoneal dialysis 2 | |||||||||
| - Multicenter experience with low-sodium peritoneal dialysis solutions | |||||||||
| Simon Davies, Stoke-on-Trent, UK | |||||||||
| - PDGF in renal and peritoneal fibrosis | |||||||||
| Peter Margetts, Ontario, Canada | |||||||||
| - Peritoneal infection/inflammation and patient outcomes: data from the GLOBAL fluid study | |||||||||
| Nick Topley, Cardiff, UK | |||||||||
| - Current outcomes in peritoneal dialysis | |||||||||
| Giovanni Cancarini, Brescia, Italy | |||||||||
| • Prevention of cardiovascular risk in renal patients | |||||||||
| - Nutritional initiatives to decrease cardiovascular risk in CKD | |||||||||
| Michal Chmielewski, Gdansk, Poland | |||||||||
| - Limitations of statins in the prevention of cardiovascular events in dialysis patients | |||||||||
| Bengt Fellstrom, Uppsala, Sweden | |||||||||
| - Effect of blood pressure lowering on cardiovascular morbidity and mortality in people with chronic kidney disease | |||||||||
| Hiddo J. Lambers Heerspink, Groningen, The Netherlands | |||||||||
| - Atherosclerosis and vascular calcification and CKD - Insights from animal models | |||||||||
| Ziad A. Massy, Amiens, France | |||||||||
| • Transplantation: New immunosuppressants | |||||||||
| - Jak-3 inhibitors | |||||||||
| Willem Weimar, Rotterdam, Netherlands | |||||||||
| - Costimulatory signal blockers | |||||||||
| Thomas Wekerle, Vienna, Austria | |||||||||
| - Is there a role for new anti-B cells and anti-complement agents in kidney transplant patients? | |||||||||
| Lionel Rostaing, Toulouse, France | |||||||||
| - Novel therapies to inhibit adhesion and coactivation pathways | |||||||||
| Flavio Vincenti, San Francisco, USA | |||||||||
| • Ciliopathies | |||||||||
| - Signaling pathways and function of primary cilia | |||||||||
| Søren Tvorup Christensen, Copenhagen, Denmark | |||||||||
| - The dynamic cilium in human diseases: the example of the OFDI syndrome | |||||||||
| Brunella Franco, Naples, Italy | |||||||||
| - How animal models for PKD mimic human disease | |||||||||
| Albert Ong, Sheffield, UK | |||||||||
| - Restoration of renal function in animal models of ciliopathies | |||||||||
| Jonathan L. Tobin, London, United Kingdom | |||||||||
| • Immunonephrology | |||||||||
| - Organization and activities of the Immunonephrology Working Group | |||||||||
| Mohamed R. Daha, Leiden, The Netherlands | |||||||||
| - Proposal from the group: validation study of the clinico-pathological classification of IgAN in Europe | |||||||||
| Rosanna Coppo, Turin, Italy | |||||||||
| - Proposals of new collaborative studies on rare diseases and recurrent glomerular diseases after transplantation | |||||||||
| Jürgen Floege, Aachen, Germany | |||||||||
| - Fair of scientific ideas | |||||||||
| Loreto Gesualdo, Foggia, Italy | |||||||||
| Monday, June 28th, 2010 | |||||||||
| • T regulatory cells in renal transplantation | |||||||||
| - T regulatory cells in alloimmune response | |||||||||
| Kathryn Wood, Oxford, UK | |||||||||
| - Mastering Treg function to promote tolerance | |||||||||
| Angus W. Thomson, Pittsburgh, USA | |||||||||
| - Adoptive cell therapy with regulatory T cells in renal transplantation | |||||||||
| Giovanna Lombardi, London, UK | |||||||||
| - Intragraft T regulatory cells in kidney transplantation | |||||||||
| Oriol Bestard, Barcelona, Spain | |||||||||
| • ERBP | |||||||||
| - ERBP as the current guidance body of European nephrology: current status | |||||||||
| Raymond Vanholder, Ghent, Belgium | |||||||||
| - ERBP position statement on choice of hemodialysis membranes | |||||||||
| James Tattersall, Leeds, UK | |||||||||
| - ERBP position statement on the KDIGO CKD-MBD guidelines | |||||||||
| Gérard London, Fleury-Mérogis, France | |||||||||
| - ERBP position statement on prevention and treatment of central vein hemodialysis catheters | |||||||||
| Raymond Vanholder, Ghent, Belgium | |||||||||
| - ERBP advice on testing of peritoneal membrane quality | |||||||||
| Wim Van Biesen, Ghent, Belgium | |||||||||
| • Treatment of glomerular diseases | |||||||||
| - Multitarget therapy for lupus nephritis | |||||||||
| David Jayne, Cambridge, UK | |||||||||
| - Current therapies in membranous nephropathy | |||||||||
| José Ballarin, Barcelona, Spain | |||||||||
| - Outcomes of recent trials in ANCA-associated vasculitis | |||||||||
| Kirsten de Groot, Offenbach, Germany | |||||||||
| - Complement regulation and haemolytic uremic syndrome | |||||||||
| David Kavanagh, Newcastle, UK | |||||||||
| • Anaemia in CKD | |||||||||
| - Haemoglobin variability in non-dialysis CKD patients | |||||||||
| A.L.M de Francisco, Santander, Spain | |||||||||
| - Hepcidin levels and erythropoietin response in CKD patients | |||||||||
| Damien R. Ashby, London, UK | |||||||||
| - Modifying iron balance in CKD patients, is BMP signalling a reasonable target? | |||||||||
| Donal Reddan, Galway, Ireland | |||||||||
| - Anaemia management in patients with CKD: European Best Practice recommendations | |||||||||
| Francesco Locatelli, Lecco, Italy | |||||||||
| • Tubular transport | |||||||||
| - Calcium in motion: from renal transporters to new concepts | |||||||||
| René Bindels, Nijmegen, The Netherlands | |||||||||
| - Distal tubular potassium channels and renal salt wasting | |||||||||
| Richard Warth, Regensburg, Germany | |||||||||
| - The epithelial sodium channel (ENaC) and its role in arterial hypertension and renal sodium retention | |||||||||
| Cristoph Korbmacher, Erlangen, Germany | |||||||||
| - Amino acid transport | |||||||||
| François Verrey, Zürich, Switzerland | |||||||||
| • Endothelin and endothelin-receptor antagonists | |||||||||
| - Pathophysiology of the endothelin system: lessons from genetically manipulated animals models | |||||||||
| Berthold Hocher, Berlin, Germany | |||||||||
| - Endothelin-1 and its antagonism in chronic kidney disease | |||||||||
| Neeraj Dhaun, Edinburgh, UK | |||||||||
| - Endothelin receptor antagonists in diabetic nephropathy | |||||||||
| René R. Wenzel, Zell am See, Austria | |||||||||
| • The bone and CKD | |||||||||
| - The culprit of osteoporosis in CKD | |||||||||
| Marie-Hélène Lafage-Proust, Saint-Etienne, France | |||||||||
| - Calcium metabolism changes after transplantation | |||||||||
| Pieter Evenepoel, Leuven, Belgium | |||||||||
| - Adynamic bone disease: from bone to vessels | |||||||||
| Jordi Bover, Barcelona, Spain | |||||||||
| • Nephroprotection | |||||||||
| - Screening for albuminuria in the prevention of renal function loss | |||||||||
| Ronald T. Gansevoort, Groningen, Netherlands | |||||||||
| - RAAS blockade in native and grafted kidneys | |||||||||
| Leszek Tylicki, Gdansk, Poland | |||||||||
| - Pleiotropic effects of ATR1 blockers | |||||||||
| Giuseppe Remuzzi, Bergamo, Italy | |||||||||
| • Regulatory aspects of kidney function | |||||||||
| - (Patho)physiology of intercalated cells | |||||||||
| Carsten Wagner, Zürich, Switzerland | |||||||||
| - The serum and glucocorticoid inducible kinase SGK1 in the regulation of renal function and blood pressure | |||||||||
| Florian Lang, Tübingen, Germany | |||||||||
| - Impact of trans- and paracellular permeability | |||||||||
| Markus Bleich, Kiel, Germany | |||||||||
| return to top | |||||||||
| LITERATURE UPDATES | |||||||||
| Saturday, June 26th, 2010 | |||||||||
| • Clinical nephrology | |||||||||
| - Optimal management of hypertension | |||||||||
| Giuseppe Mancia, Milan, Italy | |||||||||
| - Side effects in treatment in nephrology | |||||||||
| David Jayne, Cambridge, UK | |||||||||
| - Therapy of glomerular diseases | |||||||||
| Alan Salama, London, UK | |||||||||
| • Transplantation | |||||||||
| - Renal preservation | |||||||||
| Speaker to be confirmed | |||||||||
| - Immunosuppression | |||||||||
| Uwe Heemann, Munich, Germany | |||||||||
| - Polyomavirus infection in renal transplantation | |||||||||
| Cristina Costa, Turin, Italy | |||||||||
| - Recurrent renal diseases | |||||||||
| Pierre Cochat, Lyon, France | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| • Dialysis | |||||||||
| - Fluid balance and core temperature control to improve hemodynamic stability | |||||||||
| Speaker to be confirmed | |||||||||
| - Diffusive and convective toxin removal by dialysis procedures | |||||||||
| Detlef Krieter, Würzburg, Germany | |||||||||
| - Vaccination and hygiene strategies for infection prevention | |||||||||
| Michel Jadoul, Louvain, Belgium | |||||||||
| - Oxidative stress in dialysis patients: causes and consequences. | |||||||||
| Jan Kielstein, Hannover, Germany | |||||||||
| return to top | |||||||||
| COMPACT PRIMERS | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| • Treatment of AKI in special populations | |||||||||
| - Renal transplantation | |||||||||
| Christophe Legendre, Paris, France | |||||||||
| - AKI in children | |||||||||
| Franz Schaefer, Heidelberg, Germany | |||||||||
| - AKI in HIV-infected patients | |||||||||
| Paul L. Kimmel, Washington, USA | |||||||||
| - Treatment of AKI in oncology patients | |||||||||
| Claudio Ronco, Vicenza, Italy | |||||||||
| • Practices in renal transplantation | |||||||||
| - Cardiovascular screening of potential transplant recipients | |||||||||
| Alan G. Jardine, Glasgow, UK | |||||||||
| - Sense or non sense of screening transplant recipients for malignancies | |||||||||
| Bryce Kiberd, Halifax, Canada | |||||||||
| - Pregnancy in transplant donors | |||||||||
| Anna Varberg Reisaeter, Oslo, Norway | |||||||||
| - Donor registries: the common Living Donor Database within Scandinavia | |||||||||
| Ole Oyen, Oslo, Norway | |||||||||
| Monday, June 28th, 2010 | |||||||||
| • Peritoneal dialysis in special patients | |||||||||
| - Volume in PD: the heart of the matter | |||||||||
| Wim van Biesen, Ghent, Belgium | |||||||||
| - Peritoneal dialysis in cirrhotic patients: effects on portal hypertension | |||||||||
| Rafael Selgas, Madrid, Spain | |||||||||
| - Optimal use of peritoneal dialyis in diabetic patients | |||||||||
| Francisco Coronel, Madrid, Spain | |||||||||
| return to top | |||||||||
| PRE-CONGRESS CME COURSES | |||||||||
| Friday, June 25th, 2010 | |||||||||
| • Animal models of renal diseases | |||||||||
| • Transplant immunology | |||||||||
| • Renal ultrasonography | |||||||||
| • Omics in Nephrology | |||||||||
| • Rheumatology for nephrologists | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| • Rare renal diseases | |||||||||
| return to top | |||||||||
| LATE BREAKING TRIALS | |||||||||
| Saturday, June 26th, 2010 | |||||||||
| • Late breaking trials 1 | |||||||||
| Sunday, June 27th, 2010 | |||||||||
| • Late breaking trials 2 | |||||||||
| return to top |
